MedTrace Logo

Selegiline Patch for Treatment of Nicotine Dependence

NCT01330030 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 243

Last updated 2016-08-10

Study results available
· View outcomes & findings →

Summary

Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.

Conditions

  • Tobacco Use Disorder

Interventions

DRUG

Selegiline

6mg/24 hrs for 8 weeks

OTHER

matching placebo

placebo/24hrs for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Joel D Killen · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2008-08-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01330030 on ClinicalTrials.gov